Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
76,35 USD | +0,73% | +1,57% | +13,36% |
03/05 | Angle-aandelen stijgen na overeenkomst met AstraZeneca over de ontwikkeling van assays | AN |
03/05 | Angle aandelen stijgen na overeenkomst met AstraZenaca voor de ontwikkeling van een assay | AN |
Vakgebied
- productverkoop (95,6%). De nettoverkoop wordt per behandelingsgebied verdeeld tussen oncologie (39,2%), hart- en vaatziekten, nierziekten en stofwisselingsziekten (24,2%), ademhalings- en auto-immuunziekten (13,9%), en overige (22,7%; ontstekingsziekten, neurologische ziekten, maag-, darm- en infectieziekten);
- inkomsten uit samenwerking (4,4%).
De netto-omzet is als volgt geografisch verdeeld: het Verenigd Koninkrijk (7,4%), Europa (21,2%), Amerika (45,3%) en Afrika-Azië-Australië (26,1%).
Aantal werknemers: 89 900
Verkoop per activiteit
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Oncology
37,4
%
| 11 878 | 33,0 % | 13 793 | 37,4 % | +16,12% |
Cardiovascular, Renal and Metabolism
23,1
%
| 7 459 | 20,7 % | 8 515 | 23,1 % | +14,16% |
Rare Disease
16,9
%
| 5 726 | 15,9 % | 6 246 | 16,9 % | +9,08% |
Respiratory and Immunology
13,3
%
| 4 680 | 13,0 % | 4 913 | 13,3 % | +4,97% |
Alliance
3,1
%
| - | - | 1 149 | 3,1 % | - |
Other Medicines
2,6
%
| 1 319 | 3,7 % | 946 | 2,6 % | -28,29% |
Vaccines and Immune Therapies
2,2
%
| 3 845 | 10,7 % | 814 | 2,2 % | -78,83% |
Collaboration
1,3
%
| 1 098 | 3,1 % | 478 | 1,3 % | -56,50% |
Verkoop per regio
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
39,6
%
| 14 027 | 39,0 % | 14 578 | 39,6 % | +3,93% |
China
12,8
%
| 4 662 | 12,9 % | 4 724 | 12,8 % | +1,32% |
Japan
7,9
%
| 3 236 | 9,0 % | 2 928 | 7,9 % | -9,51% |
United Kingdom
7,4
%
| 2 530 | 7,0 % | 2 709 | 7,4 % | +7,07% |
Other Rest of Europe
6,8
%
| 2 197 | 6,1 % | 2 502 | 6,8 % | +13,89% |
Germany
4,6
%
| 1 544 | 4,3 % | 1 689 | 4,6 % | +9,36% |
Other Asia, Africa and Australasia
4,5
%
| 1 953 | 5,4 % | 1 645 | 4,5 % | -15,77% |
Sweden
3,7
%
| 1 397 | 3,9 % | 1 371 | 3,7 % | -1,89% |
Other Americas
3,7
%
| 954 | 2,6 % | 1 354 | 3,7 % | +41,94% |
France
2,5
%
| 899 | 2,5 % | 927 | 2,5 % | +3,12% |
Canada
2,1
%
| 947 | 2,6 % | 778 | 2,1 % | -17,82% |
Spain
1,8
%
| 599 | 1,7 % | 681 | 1,8 % | +13,73% |
Italy
1,8
%
| 597 | 1,7 % | 654 | 1,8 % | +9,61% |
Australia
0,9
%
| 464 | 1,3 % | 314 | 0,9 % | -32,32% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01-10-12 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01-08-21 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-01-20 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-23 |
Regina Danielson
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Chief Tech/Sci/R&D Officer | - | 18-05-23 | |
Pam Cheng
COO | Chief Operating Officer | 53 | 01-06-15 |
Jeffrey Pott
CMP | Compliance Officer | - | 01-01-95 |
Corporate Officer/Principal | 63 | 01-01-02 | |
Iskra Reic
PRN | Corporate Officer/Principal | - | 01-01-01 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01-10-17 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01-02-13 |
Philip Broadley
BRD | Director/Board Member | 63 | 27-04-17 |
Director/Board Member | 68 | 01-04-99 | |
Marc Dunoyer
PRN | Corporate Officer/Principal | 71 | 01-06-13 |
Andreas Rummelt
BRD | Director/Board Member | 66 | 01-08-21 |
Michel Demaré
CHM | Chairman | 67 | 01-09-19 |
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01-10-12 |
Deborah DiSanzo
BRD | Director/Board Member | 64 | 01-12-17 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01-08-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 550 235 025 | 1 495 910 888 ( 96,50 %) | 0 | 96,50 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
18 750 000 | 75.00% | 1 196 097 188 $ | |
32 100 518 | 9.06% | 802 167 869 $ | |
108 923 023 | 37.58% | 678 032 747 $ | |
NIOX GROUP PLC 16.81% | 71 065 878 | 16.81% | 57 455 341 $ |
CELLECTIS S.A. 22.30% | 16 000 000 | 22.30% | 42 992 640 $ |
ADC THERAPEUTICS SA 4.86% | 4 011 215 | 4.86% | 18 010 355 $ |
INNATE PHARMA 9.26% | 7 485 500 | 9.26% | 17 664 283 $ |
3 584 230 | 3.63% | 655 914 $ | |
884 956 | 1.99% | 69 027 $ |
Bedrijfsgegevens
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.co.ukBedrijven van de groep
Naam | Categorie en sector |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. |
Miscellaneous Commercial Services
|
Pharmaceuticals: Major
| |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. |
Miscellaneous Commercial Services
|
R&Q Beta Co. Plc
R&Q Beta Co. Plc Insurance Brokers/ServicesFinance R&Q Beta Co. Plc provides insurance services. The company was founded in 1994 and is headquartered in Cambridge, the United Kingdom. |
Insurance Brokers/Services
|
AstraZeneca India Pvt Ltd.
AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology AstraZeneca India Pvt Ltd. operates as a biopharmaceutical company. The company was founded in 1979 and is headquartered in Bangalore, India. |
Pharmaceuticals: Major
|
Astrazeneca Holdings BV
| |
AstraZeneca Share Trust Ltd.
AstraZeneca Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Share Trust Ltd. is a British company that provides business support services. The private company is located in the UK. |
Miscellaneous Commercial Services
|
AstraZeneca Employee Share Trust Ltd.
AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The private company is located in the UK. |
Miscellaneous Commercial Services
|
Astrazeneca Treasury BV
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
+8,08% | 167 mld. | |
-3,40% | 157 mld. | |
+1,72% | 123 mld. |